Showing 3611-3620 of 4680 results for "".
- Merz to Acquire Ulthera, Inc.https://practicaldermatology.com/news/20140630-merz_to_acquire_ulthera_inc/2459184/Merz and Ulthera have entered a definitive merger agreement pursuant to which Merz will acquire Ulthera, Inc, a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications using its therapeutic ultrasound platform technology. Valued
- FDA Limits Use of Nizoralhttps://practicaldermatology.com/news/20130730-fda_limits_use_of_nizoral/2459489/The FDA has limited the use of Nizoral (ketoconazole) oral tablets, warning that the oral tablets can cause severe liver injuries and adrenal gland problems and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes and added a new Medication Gu
- Georgia Governor Signs AMA Model Legislationhttps://practicaldermatology.com/news/20130520-georgia_governor_signs_ama_model_legislation/2459538/Georgia lawmakers enacted legal protections for physicians engaged in quality and delivery improvement initiatives included in the federal health care reform law. This first-of-its-kind legislation reinforces the concept that medical decisions are made based on a patient's unique medical needs. The
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al
- Obagi and Suneva Partner to Distribute Facial Rejuvenation Complexhttps://practicaldermatology.com/news/20130201-obagi_and_suneva_parter_to_distribute_facial_rejuvenation_complex/2459622/Obagi Medical Products and Suneva Medical jointly announced a partnership to co-distribute ReGenica Facial Rejuvenation Complex, a product that accelerates the appearance of post-laser skin through the fusion of stem cells and growth factors. It contains the Multipotent CCM Complex (Cell Conditioned
- Gut Microbiome May Affect How Metastatic Melanoma Responds to Immunotherapyhttps://practicaldermatology.com/news/gut-microbiome-may-affect-how-metastatic-melanoma-responds-to-immunotherapy/2457986/The gut microbiome can influence how metastatic melanoma responds to immunotherapy, researchers from The University of Texas MD Anderson Cancer Center report in the journal
- Dermatologist Launches Kickstarter Campaignhttps://practicaldermatology.com/news/20140422-dermatologist_launches_kickstarter_campaign/2459261/Steven Feldman, MD, PhD, is spearheading a new Kickstarter campaign entitled “Changes in the Landscape” for the Coalition for Peace and Justice, an organization that welcomes all individuals and g
- ASA Awards: Jon M. Hanifin, MD, Wins David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/asa-awards-jon-m-hanifin-md-wins-david-martin-carter-mentor-award/2461728/The American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan. <
- Burt's Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-care-outperforms-md-recommended-regimen/2457650/Burt’s Bees nature-based sensitive skin regimen is well-tolerated as well as clinically and statistically superior to a leading dermatologist-recommended synthetic regimen, according to a
- Zylö Therapeutics: Adam Friedman, MD to Present Data at AAD Annual Meetinghttps://practicaldermatology.com/news/zyl-therapeutics-adam-friedman-md-to-present-data-at-aad-annual-meeting/2457886/Zylö Therapeutics, a nanotechnology-based biopharmaceutical company dedicated to bringing innovative technologies to multiple facets of medicine, announced that preclinical data, utilizing Zylö’s patented hydrogel-derived Na